GlycoMimetics, Inc. - Common Stock (NQ:GLYC)

0.1570 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about GlycoMimetics, Inc. - Common Stock

< Previous 1 2 3 Next >

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

June 05, 2025

From GlycoMimetics, Inc.

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders

May 18, 2025

From Halper Sadeh LLC

Via GlobeNewswire

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

May 16, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, FARO, AVDX, GLYC on Behalf of Shareholders

May 09, 2025

From Halper Sadeh LLC

Via GlobeNewswire

GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting

November 06, 2024

From GlycoMimetics, Inc.

Via Business Wire

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

October 31, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders

October 29, 2024

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq – PFIE), Cepton, Inc. (Nasdaq – CPTN), GlycoMimetics, Inc. (Nasdaq – GLYC), ARC Document Solutions, Inc. (NYSE - ARC)

October 29, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders

October 29, 2024

From Ademi LLP

Via Business Wire

GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders

October 29, 2024

From Halper Sadeh LLC

Via Business Wire

GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

October 29, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

October 29, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

July 25, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

June 04, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

May 29, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

May 06, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

April 25, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

March 27, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

March 13, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

February 26, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 12, 2024

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

January 04, 2024

From GlycoMimetics, Inc.

Via Business Wire

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

January 03, 2024

From Apollomics Inc.

Via GlobeNewswire

GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia

December 10, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

November 09, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

November 03, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023

October 20, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

September 06, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference

September 05, 2023

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2023

From GlycoMimetics, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.